$ALT
Altimmune Inc Stock $alt

$alt Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000114420413027117 Filed on May 08, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$1.656K	$6.480M	$6.150M
YoY Change	-99.97%	5.37%	-3.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.330M	$2.280M	$2.950M
YoY Change	-16.19%	-22.71%	-40.28%
% of Gross Profit
Research & Development	$3.403M	$5.233M	$4.705M
YoY Change	-30.82%	11.22%	-19.16%
% of Gross Profit
Depreciation & Amortization	$41.85K	$52.60K	$90.00K
YoY Change	-40.21%	-41.55%	-25.0%
% of Gross Profit
Operating Expenses	$5.777M	$7.566M	$7.740M
YoY Change	-25.7%	-2.25%	-28.85%
Operating Profit	-$1.482M	-$1.091M	-$1.591M
YoY Change	1.61%	-31.43%	-64.96%
Interest Expense	$100.0K	$99.79K	$3.028K
YoY Change	-10.17%	3195.61%	-80.38%
% of Operating Profit
Other Income/Expense, Net	$256.6K	-$1.011M	-$938.8K
YoY Change	-64.26%	7.68%	-138.1%
Pretax Income	-$1.225M	-$2.102M	-$2.529M
YoY Change	65.47%	-16.91%	21.86%
Income Tax	$11.21K	$9.743K	$150.4K
% Of Pretax Income
Net Earnings	-$1.236M	-$2.111M	-$2.680M
YoY Change	63.42%	-21.21%	29.11%
Net Earnings / Revenue	-74660.14%	-32.58%	-43.58%
Basic Earnings Per Share	-$0.02	-$0.04	-$0.06
Diluted Earnings Per Share	-$0.02	-$0.04	-$0.06
COMMON SHARES
Basic Shares Outstanding	49.46M shares	48.37M
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.80M	$12.90M	$15.30M
YoY Change	33.9%	-15.69%	57.73%
Cash & Equivalents	$15.79M	$12.87M	$15.30M
Short-Term Investments
Other Short-Term Assets	$700.0K	$600.0K	$800.0K
YoY Change	0.0%	-25.0%	-55.56%
Inventory
Prepaid Expenses
Receivables	$5.200M	$5.600M	$5.400M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$21.69M	$19.07M	$21.53M
YoY Change	4.88%	-11.43%	5.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$460.1K	$456.8K	$702.0K
YoY Change	-26.45%	-34.92%	-36.18%
Goodwill	$2.348M	$2.348M	$2.348M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$85.91K	$99.58K	$174.5K
YoY Change	-42.91%	-42.94%	74.53%
Total Long-Term Assets	$2.894M	$2.905M	$3.225M
YoY Change	-7.36%	-9.93%	-7.86%
TOTAL ASSETS
Total Short-Term Assets	$21.69M	$19.07M	$21.53M
Total Long-Term Assets	$2.894M	$2.905M	$3.225M
Total Assets	$24.59M	$21.97M	$24.75M
YoY Change	3.27%	-11.24%	3.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.993M	$1.290M	$1.411M
YoY Change	45.08%	-8.57%	-63.83%
Accrued Expenses	$2.100M	$3.300M	$2.900M
YoY Change	-32.26%	13.79%	3.57%
Deferred Revenue
YoY Change
Short-Term Debt	$1.168M	$1.329M	$857.8K
YoY Change		54.96%
Long-Term Debt Due	$1.000M	$1.000M	$195.4K
YoY Change	120.0%	411.74%
Total Short-Term Liabilities	$7.722M	$7.788M	$5.314M
YoY Change	36.46%	46.55%	-20.69%
LONG-TERM LIABILITIES
Long-Term Debt	$1.218M	$1.460M	$2.235M
YoY Change	-38.61%	-34.65%
Other Long-Term Liabilities	$577.7K	$580.2K	$556.0K
YoY Change	2.28%	4.36%	-91.17%
Total Long-Term Liabilities	$1.796M	$2.041M	$2.791M
YoY Change	-29.54%	-26.88%	-55.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.722M	$7.788M	$5.314M
Total Long-Term Liabilities	$1.796M	$2.041M	$2.791M
Total Liabilities	$11.37M	$12.03M	$10.98M
YoY Change	10.76%	9.53%	-15.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$202.0M	-$200.7M	-$196.4M
YoY Change	2.45%	2.22%
Common Stock	$215.4M	$210.9M	$209.1M
YoY Change	2.73%	0.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.22M	$9.943M	$13.77M
YoY Change
Total Liabilities & Shareholders Equity	$24.59M	$21.97M	$24.75M
YoY Change	3.27%	-11.24%	3.57%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$1.236M	-$2.111M	-$2.680M
YoY Change	63.42%	-21.21%	29.11%
Depreciation, Depletion And Amortization	$41.85K	$52.60K	$90.00K
YoY Change	-40.21%	-41.55%	-25.0%
Cash From Operating Activities	-$490.0K	$260.4K	$791.4K
YoY Change	-81.85%	-67.09%	-137.91%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	$25.47K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$70.00K
YoY Change		-100.0%
Cash From Investing Activities	-$40.00K	-$25.47K	$67.40K
YoY Change		-137.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$53.41K	$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.460M	-$60.36K	$3.205M
YoY Change	-527.16%	-101.88%	25014.53%
NET CHANGE
Cash From Operating Activities	-490.0K	$260.4K	$791.4K
Cash From Investing Activities	-40.00K	-$25.47K	$67.40K
Cash From Financing Activities	3.460M	-$60.36K	$3.205M
Net Change In Cash	2.930M	$174.6K	$4.063M
YoY Change	-183.48%	-95.7%	-295.87%
FREE CASH FLOW
Cash From Operating Activities	-$490.0K	$260.4K	$791.4K
Capital Expenditures	-$40.00K	$25.47K
Free Cash Flow	-$450.0K	$234.9K	$791.4K
YoY Change	-83.33%	-70.31%	-137.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-217328	USD
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001326190
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49460686	shares
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	PHARMATHENE, INC
CY2013Q1	dei	Trading Symbol TradingSymbol	PIP
CY2013Q1	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3294315	USD
CY2012Q4	pip	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	2328877	USD
CY2013Q1	pip	Proceeds From Issuance Of Long Term Debt And Warrants ProceedsFromIssuanceOfLongTermDebtAndWarrants		USD
CY2012Q1	pip	Proceeds From Issuance Of Long Term Debt And Warrants ProceedsFromIssuanceOfLongTermDebtAndWarrants	2500000	USD
CY2013Q1	pip	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate	0.12	pure
CY2012Q1	pip	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate	0.12	pure
CY2013Q1	pip	Supplemental Warrant Issued In Connection With Long Term Debt SupplementalWarrantIssuedInConnectionWithLongTermDebt		USD
CY2012Q1	pip	Supplemental Warrant Issued In Connection With Long Term Debt SupplementalWarrantIssuedInConnectionWithLongTermDebt	69876	USD
CY2009Q3	pip	Warrant Expiration Date WarrantExpirationDate	2015-01-28
CY2012Q1	pip	Warrant Expiration Date WarrantExpirationDate	2022-03-30
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1289627	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1697280	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-219012	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	210877892	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	210495905	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	328581	USD
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	548664	USD
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11600000	shares
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11500000	shares
CY2013Q1	us-gaap	Assets Assets	21972385	USD
CY2012Q4	us-gaap	Assets Assets	22741404	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	19067512	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	19795845	USD
CY2013Q1	us-gaap	Billed Contract Receivables BilledContractReceivables	1865916	USD
CY2012Q4	us-gaap	Billed Contract Receivables BilledContractReceivables	2432641	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12873411	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12701517	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15304189	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11236771	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	6475138	USD
CY2012Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	46584	shares
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	171894	USD
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48416483	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48352651	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48416483	shares
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4067418	USD
CY2013Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2201390	USD
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48352651	shares
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	4842	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	4835	USD
CY2012Q1	us-gaap	Contracts Revenue ContractsRevenue	6149052	USD
CY2013Q1	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	20000	USD
CY2012Q1	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	500000	USD
CY2012Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1.61
CY2013Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2012Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5620128	shares
CY2012Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1295613	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2013Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9743	USD
CY2012Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	150405	USD
CY2013Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	9743	USD
CY2012Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	150405	USD
CY2013Q1	us-gaap	Deferred Revenue DeferredRevenue	874404	USD
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	1381755	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	52602	USD
CY2012Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	85910	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2678	USD
CY2012Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	4034	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2000000	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	950800	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
CY2012Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	66626	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2279795	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2948481	USD
CY2013Q1	us-gaap	Goodwill Goodwill	2348453	USD
CY2012Q4	us-gaap	Goodwill Goodwill	2348453	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2101642	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2529483	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9743	USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	150405	USD
CY2012Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	131338	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-507351	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-495372	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-39486	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-137362	USD
CY2013Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-400645	USD
CY2012Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1254867	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-407653	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-35280	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-566725	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3278062	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	99791	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	3028	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	67360	USD
CY2012Q1	us-gaap	Interest Paid InterestPaid	3028	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	783	USD
CY2012Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2988	USD
CY2013Q1	us-gaap	Liabilities Liabilities	12029620	USD
CY2012Q4	us-gaap	Liabilities Liabilities	11067564	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21972385	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22741404	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7787575	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7488416	USD
CY2013Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	999996	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	749997	USD
CY2013Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1460417	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1704108	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2666519	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	580238	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1010908	USD
CY2012Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-938787	USD
CY2013Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	7565872	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	7739748	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1090734	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1590696	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	579427	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-60361	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3204614	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25468	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	67400	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	260401	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	791370	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-2111385	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-2679888	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	99578	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	113130	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1684	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	13369	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2113069	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6123	USD
CY2012Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52915	USD
CY2013Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	32431	USD
CY2012Q1	us-gaap	Paid In Kind Interest PaidInKindInterest		USD
CY2013Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		USD
CY2012Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	220234	USD
CY2013Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	112500	USD
CY2012Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25468	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	614388	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	547245	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53413	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		USD
CY2013Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities		USD
CY2012Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-32960	USD
CY2013Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-1274	USD
CY2012Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	857808	USD
CY2013Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities		USD
CY2012Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	100000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2012Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	67400	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	456842	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	483976	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5233475	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4705357	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-200720957	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-198609572	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	328581	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	548664	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	60000	shares
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	15948	shares
CY2013Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	1329233	USD
CY2012Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	1330507	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	9942765	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	11673840	USD
CY2013Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	3713797	USD
CY2012Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	4114442	USD
CY2013Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-905777	USD
CY2012Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-991662	USD
CY2013Q1	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Use of Estimates</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our intangible assets, the amount of our net operating losses, our share-based compensation, the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates<font style="FONT: 10pt Times New Roman, Times, Serif">.</font></p> <!--EndFragment--></div> </div>
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48359181	shares
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48269894	shares

Files In Submission

Name	View Source	Status
0001144204-13-027117-index-headers.html	Edgar Link	pending
0001144204-13-027117-index.html	Edgar Link	pending
0001144204-13-027117.txt	Edgar Link	pending
0001144204-13-027117-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
pip-20130331.xml	Edgar Link	completed
pip-20130331.xsd	Edgar Link	pending
pip-20130331_cal.xml	Edgar Link	unprocessable
pip-20130331_def.xml	Edgar Link	unprocessable
pip-20130331_lab.xml	Edgar Link	unprocessable
pip-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v341092_10q.htm	Edgar Link	pending
v341092_ex10-62.htm	Edgar Link	pending
v341092_ex31-1.htm	Edgar Link	pending
v341092_ex31-2.htm	Edgar Link	pending
v341092_ex32-1.htm	Edgar Link	pending
v341092_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALT
Altimmune Inc Stock $alt

2013 Q2 Form 10-Q Financial Statement

#000114420413027117 Filed on May 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT Altimmune Inc Stock $alt

2013 Q2 Form 10-Q Financial Statement

#000114420413027117 Filed on May 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT
Altimmune Inc Stock $alt